4EBF33F3-DA34-4866-81E5-F2D50A18D413
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 37.352168199737186
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.534
- MYC_TARGETS_V2+0.518
- MYC_TARGETS_V1+0.480
- E2F_TARGETS+0.431
- DNA_REPAIR+0.426
- G2M_CHECKPOINT+0.381
- CHOLESTEROL_HOMEOSTASIS+0.374
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.364
- MTORC1_SIGNALING+0.347
- NOTCH_SIGNALING+0.341
Top 10 suppressed
- ANGIOGENESIS-0.383
- IL6_JAK_STAT3_SIGNALING-0.357
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.354
- COAGULATION-0.346
- TNFA_SIGNALING_VIA_NFKB-0.336
- INTERFERON_GAMMA_RESPONSE-0.303
- INFLAMMATORY_RESPONSE-0.298
- IL2_STAT5_SIGNALING-0.269
- MYOGENESIS-0.268
- COMPLEMENT-0.256
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | EEE5E45B-D2E3-4CFA-AC5F-8AE1EC2CB61C | — | — | 0.887 |
| 2 | 2CF24C43-7C9D-4395-8C82-5A80361F9980 | — | — | 0.875 |
| 3 | MDT-AP-0843 | Med | Medulloblastoma | 0.874 |
| 4 | DEACC29A-6DEF-4728-AFEB-15D7BDA850CA | — | — | 0.871 |
| 5 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.868 |
| 6 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.864 |
| 7 | SRR8518170 | — | E | 0.860 |
| 8 | SRR10900021 | — | — | 0.858 |
| 9 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.858 |
| 10 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.534 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.518 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.431 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.426 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.381 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.374 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.364 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.347 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.341 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.302 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.277 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.253 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.203 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.184 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.168 | Inavolisib | — uncovered |
| PEROXISOME | 0.129 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.081 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.072 | Inavolisib | — uncovered |